mortality/aging
• all die by 29 weeks of age, with an average of 10 weeks
(J:75500)
|
nervous system
• 11 of 25 develop seizures by 9 weeks of age; symptoms include episodes of front-paw tremors followed by spasms of hind legs
|
• beyond 6 weeks, mice exhibit epileptiform activity associated with tonic-clonic seizures
• mice exhibit subclinical electrographic seizures lasting for at least 10 seconds largely without obvious behavioral changes unlike in wild-type mice
• at 6 weeks, two of seven mice display behavioral changes characteristic of tonic-clonic activity
• at 9 weeks, three of seven mice display behavioral changes characteristic of tonic-clonic activity
|
• mice exhibit isolated interictal spikes, short trains of repetitive spike lasting less than 5 seconds and long runs of repetitive spikes lasting between 5 and 10 seconds
• spike waves are more frequent at 9 weeks than at 6 weeks
• however, treatment with rapamycin reduces the severity of electrographic abnormalities
|
hydrocephaly
(
J:75500
)
• often see hydrocephalus of the lateral ventricles
|
• 43% increased in brain size at 10-14 weeks of age, but not at 4 weeks
(J:75500)
• variable with apparent enlargement of cortical, hippocampal and cerebellar structures
(J:149829)
|
• prominent astrogliosis in the hippocampus and the sub-pial surface
|
• disorganization of the dentate gyrus at 10 weeks of age, characterized by marked undulation of the granule-cell layer
• intercellular spaces between granule-cell bodies, containing thick neuronal dendrites and astrocytes are expanded
• granule cells of the dentate gyrus have a greater surface area (are enlarged)
|
• sclerosis of the pyramidal cell layer of the CA3
|
• reduction in pyramidal cell density of the cornu ammonis
|
• enlarged cerebellum
|
• thickened cerebellar folia
|
• multifocal persistence of the external granular cell layer at the pial surface
|
• those Purkinje cells remaining are atrophic or dysplastic as indicated by dendritic coarsening and axonal swelling
|
• partial loss of Purkinje cells
|
• soma size is increased in granule neurons at 10 weeks of age
|
• mutants exhibit heterotopic neuronal clusters scattered in the molecular layer
• the molecular layer is thickened, especially at sites of heterotopic lesions
• disorganization, dysplasia, gliosis and elevated myelination in the molecular layer
|
• gliosis in the molecular layer
• astrogliosis is visible in close proximity to the affected heterotopic neurons in the cerebellum and in the hippocampus and the sub-pial surface
|
• cortical Pten-negative neurons are hypertrophic
• at P12, soma size of Pten-negative neurons is increased 1.7-fold compared with wild-type neurons
• adult Pten-negative neurons are larger than in wild-type mice
• however, Pten-negative pyramidal neurons do not exhibit an increase in size with age and treatment with rapamycin suppresses neuron hypertrophy
|
behavior/neurological
• 11 of 25 develop seizures by 9 weeks of age; symptoms include episodes of front-paw tremors followed by spasms of hind legs
|
• beyond 6 weeks, mice exhibit epileptiform activity associated with tonic-clonic seizures
• mice exhibit subclinical electrographic seizures lasting for at least 10 seconds largely without obvious behavioral changes unlike in wild-type mice
• at 6 weeks, two of seven mice display behavioral changes characteristic of tonic-clonic activity
• at 9 weeks, three of seven mice display behavioral changes characteristic of tonic-clonic activity
|
• mice exhibit isolated interictal spikes, short trains of repetitive spike lasting less than 5 seconds and long runs of repetitive spikes lasting between 5 and 10 seconds
• spike waves are more frequent at 9 weeks than at 6 weeks
• however, treatment with rapamycin reduces the severity of electrographic abnormalities
|
neoplasm
• brain lesions are categorized as hamartomas
• however, do not develop glioblastomas between 4-19 weeks of age
|
growth/size/body
• variable with apparent enlargement of cortical, hippocampal and cerebellar structures
(J:149829)
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
brain disease | DOID:936 | J:149829 | ||
Cowden syndrome | DOID:6457 |
OMIM:PS158350 |
J:75500 |